



Adaptive
biotechnologies™

Third Quarter 2021
Earnings Conference Call


Safe Harbor

This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results and other future conditions. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. All statements, other than statements of historical facts, contained in this presentation are forward looking statements, including statements regarding the ability to map adaptive immune responses to target disease states, the ability to leverage any such findings to advance solutions to diagnose, treat and prevent infectious diseases; regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective products and product candidates, including clonoSEQ, immunoSEQ and T-Detect products; discovery and development of neutralizing antibodies, FDA clearance or authorization of any products; planned non-IDE clinical studies, clinical trials and preclinical activities, research and development costs, current and prospective collaborations, including the collaboration evidenced by our license agreement with Vaccibody; the estimated size of the market for our products and product candidates; the timing and success of our development and commercialization of our anticipated product candidates; the availability of alternative therapies for our target markets; and the other risks and uncertainties described in our filings with the Securities and Exchange Commission including the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K, including our most recent Annual Report on Form 10-K filed on February 24, 2021. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Risks and uncertainties could cause actual results to differ materially from those expressed in our forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

Q3 2021 Key Highlights



clonoSEQ brand: Increase in clinical adoption and pharma partnerships



clonoSEQ Clinical Testing

- Q3'21 test delivered volume +47% vs P/Y; +8% vs P/Q
 - ~260 ordering accounts; ~1,020 ordering HCPs in Q3
- Launched IGHV status for CLL patients
 - Enable HCPs to assess IGHV mutation status and obtain trackable sequence for MRD monitoring from one ID blood sample.

MRD Pharma Portfolio

- Significant value driver to the overall MRD franchise
- Structured to contribute sequencing and development revenue
 - >\$330M in future regulatory milestones pipeline
 - Recognized \$1.5M in a development milestone in Q3

clonoSEQ test volume



T-Detect COVID focus; leveraging Coverage and T-MAP pharma partnerships

T-Detect update: Infectious Disease



■ Medicare coverage for immuno-compromised patients



✓ Prioritization of timing and resource allocation to market T-Detect COVID for immunocompromised patients and prepare formal reimbursement launch in 2022

■ immuneSense Lyme study completed: nearly 2x more sensitive than STTT at detecting early signs of disease

■ Make T-Detect Lyme available by Lyme season



Leveraging Partnerships

Widening adoption of immunoSEQ T-MAP COVID / T-Detect COVID with Pharma, Biotech and Research



Published data showing key role of T cell in the wake of variants; ongoing discussions to expand studies to assess correlate of protection



Correlate of protection in immunocompromised patients



Samples in house: effectiveness of vaccine in eliciting COVID specific T-cell response



Understand T-cell response in individuals with AZ vaccine + booster developed by Clover


Progress on our open-ended growth story in Drug Discovery

Cell Therapy: identify TCRs as Therapeutics

Genentech
A Member of the Roche Group



- ✓ **Shared Product:** on track to assess efficacy and safety data with GNE to enable a decision by YE to move our lead product into early development
- ✓ **Private Product:** on track to process blood from ~60 cancer patients by YE




Vaccines: Identify Antigens for vaccines

vaccibody




- ✓ Vaccibody announced start of 2-arm Phase 1/2 trial in previously vaccinated individuals with two vaccine candidates
 - **RBD Candidate:** Vaccibody program designed to generate RBD specific antibody and T-cell immunity
 - **T Cell Candidate:** Uses Adaptive identified and validated T cell epitopes; expected to result in a broader immune response against variants



Q3 2021 Key Financial Highlights


Revenues (\$M)



¹ Includes \$2.5M in MRD milestones


² Includes \$1.5M in MRD milestones

Operating Expenses (\$M)³



³ Excludes amortization of intangible assets

Sequencing Volume



Balance Sheet & 2021 Guidance

- ~\$632M in cash, cash equivalents and marketable securities as of 09/30/2021
- Reiterate 2021 full year revenue range \$148M - \$155M


2021 remaining milestones

- Embed T-MAP COVID into SARS-CoV-2 vaccine studies
- T-Detect IBD: analysis of >5,000 IBD samples
- Confirm additional T-Detect signal(s)
- FDA decision for clonoSEQ ALL in blood
- Shared product: decision to move lead candidate into early development
- Private product: proof of concept data for ~60 cancer patients



Thank You.

Clinical portfolio and pipeline



1. clonoSEQ NHL subtypes: available to order as a CLIA-validated laboratory developed test (LDT) service. This use has not been cleared or approved by the FDA.

2. T-Detect COVID: has received Emergency Use Authorization and is not FDA cleared or approved.

3. TCR-Based Cell Therapies: product candidates in development as part of our worldwide collaboration and license agreement with Genentech. The product candidates refer to the lead clinical product candidates selected from our library of TCRs that target cancer antigens present in many cancer patients. Genentech will determine the timing of discussions with, and submissions to the FDA.

4. Neutralizing Antibodies: Product candidates in development.

5. Vaccines: Product candidates in development